August 18, 2016 04:59 PM EDT
R&D

Fol­low­ing an­oth­er PhII fail­ure, cash-strapped Cerulean chops half its staff

John Carroll

Editor & Founder

Cerulean ex­ecs end­ed Wednes­day try­ing to con­vince an­a­lysts, large­ly un­suc­cess­ful­ly, that its sec­ond Phase II fail­ure for their lead drug could be con­tained and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times